‘The more you try to divide us, the stronger and united we’ll be’: Record turnout in Mangaluru’s anti-NRC protest

French Nobel prize winning scientist Luc Montagnier has sparked a fresh controversy by claiming that the SARS-CoV-2 virus came from a lab, and is the result of an attempt to manufacture a vaccine against the AIDS virus.

In an interview given to French CNews channel and during a podcast by Pourquoi Docteur, professor Montagnier who co-discovered HIV (Human Immunodeficiency Virus) claimed the presence of elements of HIV in the genome of the coronavirus and even elements of the "germ of malaria" are highly suspect, according to a report in Asia Times.

"The Wuhan city laboratory has specialized in these coronaviruses since the early 2000s. They have expertise in this area," he was quoted as saying.

The theory that Covid-19 virus originated in the lab is making rounds for quite some time.

US President Donald Trump last week acknowledged Fox News report that the novel coronavirus may have been accidentally leaked by an intern working at the Wuhan Institute of Virology in China.

The Fox News, in an exclusive report, based on unnamed sources has claimed that though the virus is a naturally occurring strain among bats and not a bioweapon, but it was being studied in Wuhan laboratory.

The initial transmission of the virus was bat-to-human, the news channel said, adding that the "patient zero" worked at the laboratory. The lab employee was accidentally infected before spreading the disease among the common people outside the lab in Wuhan city.

Professor Montagnier was awarded the 2008 Nobel Prize in Medicine for the identification of AIDS virus, with his colleague professor Franeoise Barre-Sinoussi.

His fresh claim on coronavirus, however, received criticism from scientists, including his colleagues.

"Just in case you don't know. Dr Montagnier has been rolling downhill incredibly fast in the last few years. From baselessly defending homeopathy to becoming an antivaxxer. Whatever he says, just don't believe him," tweeted Juan Carlos Gabaldon.

As per a recent Washington Post, two years ago, the US embassy officials in China raised concerns about the insufficient biosafety at the Chinese government's Wuhan Institute of Virology where deadly viruses and infectious diseases are studied.

Though the institute, located quite close to the Wuhan wet market, is China's first biosafety level IV lab, the US state department had warned in 2018 about "serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory".

Bengaluru, May 30: Health Minister B Sriramulu banned the consumption of chewing tobacco in public places on Saturday, which is marked as World Tobacco Day. The ban would include chewing paan masala and spitting in public places.

In June 2013, the state banned the manufacture, storage, sale, or distribution of gutka and paan masala containing tobacco or nicotine as ingredients to reduce the prevalence of tobacco use. On October 26, 2016, the state proscribed all kinds of chewing tobacco, containing tobacco or nicotine or both in accordance with the Supreme Court order.

Karnataka is the second state in India to ban e-cigarettes. The state also prohibited single cigarettes. Until September 2019, the state counselled 15,698 patients in tobacco cessation centres set up in private dental colleges.

Pune/Bengaluru, Mar 25: e-Zest Solutions and Neurosynaptic Communications today announced the ReMeDi SCAN-CORONA platform, an innovative technology solution to help control the Novel COVID-19 pandemic.
As countries worldwide grapple to contain the spread and flatten the curve while treating the ones infected, the need of the hour is to deploy widespread screening and testing procedures to identify and isolate those showing symptoms.
The ReMeDi® SCAN-CORONA platform has a three-pronged approach to controlling the pandemic that makes the task of screening, testing, tracking and reporting extremely easy and manageable at a large scale.
"Mass screening and testing is the need of the hour. With the scarcity of healthcare professionals, there is a need of technology enabled platforms to do this at a large scale with minimal to no human intervention. The ReMeDi SCAN-CORONA brings together remote healthcare expertise and the power of emerging technology such as AI & ML, and promises to reduce the load on the healthcare system, so that timely care reaches the right set of people as fast as possible," said Shree Shingane - Founder and Managing Director, e-Zest Solutions GmbH.
The solution features a Corona-Screen Kit - a portable, lightweight kit that includes basic screening tools that seamlessly connect and feed data into a Patient Health Record (PHR) system without any manual intervention.
It also features a geo-tagging powered Screening app that, by importing and analyzing data from the screening tools as well as travel and medical history. The input from a third-party COVID-19 rapid testing kit further enhances the accuracy of the outcome.
"ReMeDi SCAN-CORONA helps front-line health workers to quickly assess the essential risk factors for a person digitally. It has the unique ability to track the progression of symptoms with time. The tele-consultation facility allows individuals to obtain counselling as well as consult doctors independent of location, to access timely information and guidance. We are proud to present this solution in collaboration with e-Zest," said Sameer Sawarkar CEO - Neurosynaptic.
The beauty of this solution is that while it can bring a big relief for COVID-19 screening efforts, it is equally advantageous to heavily burdened Healthcare Providers in remotely treating the non-corona health requirements as well.
The team acknowledges the valuable contribution in terms of clinical inputs for application development, from Dr Nandakumar, a renowned public health expert.
"e-Zest vision is to leverage Healthcare technologies to impact human life positively. We are happy to be part of this collaboration & look forward to it's contribution to combat the pandemic challenge globally," said Devendra Deshmukh, e-Zest CEO.
This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article.